Here is a rewritten version of the article:
The major market indexes are experiencing significant fluctuations, often reacting to tariff or Federal Reserve-related news from the White House. This volatility might lead some investors to consider withdrawing from stocks until there is more stability. However, some analysts suggest that it is still possible to identify attractive stock opportunities amidst the turbulence. They recommend five stocks that are worth considering in the current volatile market.
1. Berkshire Hathaway
Amid market chaos in 2025, Berkshire Hathaway has performed well. Shares of this conglomerate, led by Warren Buffett, have increased significantly year to date. The company offers diversification through its over 60 subsidiaries and more than 40 equity holdings. The investment discipline of Buffett and his team, along with a substantial cash reserve, positions Berkshire to take advantage of potentially favorable stock valuations.
2. Dominion Energy
Utility stocks are often reliable choices during uncertain times due to their stable cash flows and competitive protection. Dominion Energy stands out among utility stocks. Located in Virginia, home to a large hub of data centers, Dominion benefits from the high electricity demand of these facilities. The company also offers a 5% dividend yield and projects annual earnings-per-share growth between 5% and 7%.
3. Enterprise Products Partners
Enterprise Products Partners, a midstream energy leader, demonstrates resilience against market fluctuations. Historically, it maintained solid cash flow during significant crises in the oil and gas industry. The growing demand for natural gas and natural gas liquids, driven by artificial intelligence trends, is expected to benefit Enterprise. Its forward distribution yield of 6.84% could enhance total returns.
4. Pfizer
Pfizer is considered a contrarian pick. Despite a decline in COVID-19 product sales and concerns about a patent cliff, the pharmaceutical company’s stock valuation and dividend yield have become more attractive. Investors note its potential growth, driven by several products with increasing sales and a robust pipeline that includes 115 programs in clinical development.
5. Vertex Pharmaceuticals
Vertex Pharmaceuticals, with a strong performance year to date, is expected to maintain momentum. The company markets the only drugs addressing the underlying cause of cystic fibrosis and offers a promising non-opioid pain medication. Recent approvals of new drugs bolster its growth prospects. Its late-stage pipeline candidates provide additional commercial potential.
The future of stock market volatility and economic conditions remains uncertain, but Vertex is seen as capable of achieving strong gains regardless of these variables.
